Connect with us

Cannabis News

New Cannabis Delivery Agreement Between ParcelPal and Aphria (APHA) Announced

Catherine Toms



- Ad -
  • Aphria is an online cannabis marketplace that services Canada.
  • The new delivery opportunity will start by serving Calgary but will hopefully expand to other areas relatively quickly.

Canada has made history with its legalization of recreational and medical marijuana, but the key to ensuring that consumers get the most out of these policies is accessibility. Delivery services are not uncommon for food and grocery services, so why not integrate this concept into cannabis? That seems to be the idea for ParcelPal Technology Inc. and Aphria, who have just formed an agreement to deliver medical cannabis to patients, according to ParcelPal official site.

With this new project, the individual companies will begin these services in Calgary as the starting point. Patients have the opportunity to shop at the online store for Aphria, while ParcelPal takes on the responsibility of delivering products safely and legally to customers. All of these purchases can be tracked in real time and can be sent to any location in Calgary.

MADD Canada has already voiced confidence in this program, stating that one of the main benefits will be the unfettered access to medicinal cannabis as needed. However, it actually benefits the safety of the community as well, reducing the risk of impaired drivers on the roadways, as the product is delivered to them instead of requiring the venture out into the cannabis stores.

While this initiative is at its infancy, ParcelPal is expecting that other cities will quickly be included in the distribution network as it progresses. As the regulations even out, the cannabis network of ParcelPal will continue thriving and growing, which will hopefully secure them a significant portion of the $4 billion legal market.

Kelly Abbott, the President and CEO, commented that

“This sector is filled with significant growth potential” that ParcelPal could take advantage of. She added, “Management believes that we are launching our legal cannabis delivery platform at the ideal time as legislation across the country continues to expand the addressable cannabis marketplace and we are thrilled to be working with Aphria on this exciting new venture that will help to kick off the next evolution of our company.”

Over the course of the next year, Abbott is predicting that ParcelPal will have many new business opportunities, and that they are aiming to make this platform into a leader of the market. Consumers that want to learn more information about this collaboration can visit

Catherine is one of our most respected contributors and active providers of cannabis-related guides and insights here at TOC. She is very well educated with a Bachelors from Smith College, Master’s Degree from the University of Arizona, Certificate in Computer Programming College of Saint Rose and was a writing teacher at the University of Illinois. Her writing has been featured in many major publications and has full intentions of being a transparent and authentic leader for all CBD and hemp oil articles.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.